Symbols

XLO

Xilio Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 0

Ample Liquidity

High Gross Profit Margin

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About XLO

Xilio Therapeutics, Inc.

A biotech company that develops tumor-selective immuno-oncology therapies for cancer

Industry

Biological Technology

Established Date

06/18/2020

Listing Date

10/22/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.xiliotx.com

Security Type

Common stock

Office address

828 Winter Street Suite 300 Waltham MA 02451

Business

Introduction

Xilio Therapeutics, Inc., was incorporated in Delaware on June 18, 2020. The company is a clinical-stage biotechnology company that discovers and develops masking immunoecological (I-O) therapies designed to significantly improve outcomes for cancer patients. Leveraging its clinically validated masking technology and capabilities, the company is developing I-O therapies designed to be selectively activated in the tumor microenvironment to achieve long-lasting efficacy without the serious side effects associated with systemically active I-O drugs.

Company Financials

EPS

XLO has released its 2025 Q4 earnings. EPS was reported at 0.81, versus the expected -0.98, beating expectations. The chart below visualizes how XLO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

XLO has released its 2025 Q4 earnings report, with revenue of 13.69M, reflecting a YoY change of 693.85%, and net profit of 10.36M, showing a YoY change of 179.13%. The Sankey diagram below clearly presents XLO's revenue sources and cost distribution.